“Our board of directors has always been a dynamic, hard-working group,” Gamble said. “We’re grateful for the service of our returning members and we are excited to bring in four new board members this year. Kristen, David, Mike, and Kilian bring with them years of experience in the rare disease space as well as service on other nonprofit boards. We look forward to having their talent, energy, new ideas, and expertise fuel the next phase of the GFPD.”
After serving five years on board of directors, Dr. Mousumi Bose will transition to the group’s scientific advisory board. For the past five years he has carefully guided the scientific initiatives of the GFPD, including the publishing of treatment guidelines for peroxisomal biogenesis disorders in the Zellweger Spectrum.